论文部分内容阅读
目的:探讨肺耐药相关蛋白(lung resistance protein,LRP)在造血系统恶性肿瘤中的表达与临床耐药的关系。方法:应用流式细胞术(flow cytometry,FCM)检测43例造血系统恶性肿瘤患者及38例普通血液病患者LRP的表达,同时应用MTT法测定20例患者对9种化疗药物的敏感性。结果:初治组LRP的阳性率为65.52 %;复发组为83.33 %;缓解组为37.50 %;对照组为31.58 %。初治组与对照组比较差异有显著性(P<0.01);复发组与对照组比较有显著性差异(P<0.05)。初治组+复发组总阳性率68.57 %与对照组比较差异有显著性(P<0.01)。LRP阳性与LRP阴性患者的首次完全缓解率(CR1)分别为38.46 %和85.71 %,两者的差异有显著性(P<0.05);体外药敏检测与治疗疗效有相关性,临床总符合率为75 %,阳性符合率为100 %,阴性符合率为66.67 %。结论:LRP是一个有效的化疗耐药指标;LRP高表达可导致临床耐药;同时将LRP的表达和体外化疗药物敏感性的检测作为耐药指标观察,对提高临床耐药判断的准确性,指导临床化疗方案的设计有积极的意义。
Objective: To investigate the relationship between the expression of lung resistance protein (LRP) in hematopoietic malignancies and clinical drug resistance. Methods: The expression of LRP in 43 patients with hematopoietic malignancies and 38 patients with hematologic malignancies was detected by flow cytometry (FCM). Meanwhile, the sensitivity of 20 patients to 9 chemotherapeutics was determined by MTT assay. Results: The positive rate of LRP in primary treatment group was 65.52%. The recurrence group was 83.33%. The remission group was 37.50%. The control group was 31.58%. There was a significant difference between the control group and the untreated group (P <0.01). There was a significant difference between the control group and the recurrent group (P <0.05). The total positive rate of 68.57% in the newly diagnosed + relapsed group was significantly different from that in the control group (P <0.01). The first complete remission rate (CR1) was 38.46% and 85.71% in patients with LRP-positive and LRP-negative respectively, with significant difference (P <0.05). In vitro susceptibility testing was correlated with the curative effect, and the total clinical coincidence rate Was 75%, the positive coincidence rate was 100%, the negative coincidence rate was 66.67%. Conclusion: LRP is an effective indicator of chemoresistance; high expression of LRP can lead to clinical drug resistance; at the same time, the expression of LRP and the sensitivity of chemotherapeutic drugs in vitro as an indicator of drug resistance, to improve the accuracy of clinical resistance judgments, Guiding the design of clinical chemotherapy program has a positive meaning.